Smartphone App Boosts Effectiveness of Medication for Opioid Addiction
A new study suggests that adding a smartphone app-based contingency management (CM) program to medication-assisted treatment (MAT) for opioid use disorder (MOUD) significantly improves treatment outcomes. The study, published in [Source Name], found that patients who received MOUD plus CM via the WEconnect app saw a 30% reduction in opioid use days and a 23% improvement in treatment retention compared to those receiving only MOUD.
How the Study Worked
This retrospective cohort study analyzed data from opioid treatment programs across Texas between 2020 and 2023. Researchers used matched control sampling to create two groups of 300 uninsured or underinsured adults (mean age 38, 57% male, 95% White) who were similar in demographic factors. One group received MOUD alone, while the other received MOUD supplemented with CM through the WEconnect app.
The primary outcomes measured were self-reported opioid use days at the end of treatment and retention rates.
Key Findings
After adjusting for other factors, the study found that patients in the MOUD plus app-based CM group reported significantly fewer days of opioid use at the end of treatment (8.4 days) compared to the MOUD-only group (12.0 days), with a p-value less than 0.001.
Furthermore, treatment retention was significantly higher in the app-based CM group (mean duration 290.2 days) compared to the MOUD-only group (mean duration 236.1 days).
Why This Matters
The researchers highlight the potential of app-based CM as a readily implementable tool to enhance clinical care for opioid use disorder. “As a virtual treatment, app-based CM has fewer infrastructure barriers to implementation and should provide opportunities for rapid dissemination to patients,” they wrote.
“Despite the challenges of engaging patients in other app-based interventions, adding recovery-oriented, app-based CM may be one way to enhance clinical care and meet the growing needs of historically underserved patients taking MOUD,” they added.
Limitations
The study acknowledges some limitations, including the lack of random assignment to treatment groups, which could introduce selection bias. Variations in clinician effectiveness in introducing and engaging patients with the app were also noted. Additionally, the study population was predominantly White, potentially limiting generalizability to other racial and ethnic groups.
Funding and Disclosure**
This study was supported by the Texas Targeted Opioid Response and grants from the National Institute on Drug Abuse. One author reported receiving grants from KIOS/Biomedical Development Corporation outside the submitted work.
Ready to Learn More?**
Visit [source website] to access the full study and explore the latest advancements in opioid addiction treatment.